查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1860352

凝血因子市场依产品类型、适应症、製剂形式、最终用户、通路和给药途径划分－全球预测（2025-2032 年）

Coagulation Factor Concentrates Market by Product Type, Indication, Formulation, End User, Distribution Channel, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，凝血因子浓缩物市场规模将达到 171.4 亿美元，复合年增长率为 8.62%。

关键市场统计数据
基准年 2024 88.4亿美元
预计年份：2025年 95.9亿美元
预测年份 2032 171.4亿美元
复合年增长率 (%) 8.62%

清楚展现凝血因子浓缩物市场格局的演变，将治疗创新、临床应用、监管预期和供应稳定性连结起来。

凝血因子浓缩物市场正处于先进生物製药生产技术、不断发展的临床通讯协定和日益严格的供应链监管三者交汇点。本文回顾了影响包括医院、专科护理中心和分销合作伙伴在内的相关人员决策的治疗、营运和商业因素。文章强调了可靠的产品供应对于出血性疾病患者的重要性，并指出凝血因子浓缩物对于按需治疗和预防性治疗都至关重要。

随着传统血浆衍生产品向重组工程产品的转变，临床医师和采购团队在选择治疗方案时，会全面评估疗效、安全性、给药频率和总治疗成本。同时，监管机构的期望和支付方的评估也越来越关注真实世界的临床结果、疗效比较和药物经济学证据。长效生物製药的创新与持续存在的血浆供应限制和生产复杂性之间的相互作用，既给生产者、医疗服务提供者和政策相关人员带来了机会，也带来了挑战。

在后续的每个章节中，本引言为深入分析奠定了基础，重点介绍了关键的治疗类别和临床环境，并为将临床实践与强大的商业策略相结合的实用建议奠定了基础。

科学突破、不断发展的护理模式和供应链改进将如何重塑凝血因子浓缩物的治疗选择和商业策略

凝血因子浓缩物领域正经历一系列变革，这些变革的驱动力包括科学进步、医疗模式的转变以及对供应链完整性的日益重视。重组技术和製剂研发的进步使得给药间隔得以延长，输注负担得以减轻，这促使临床医生重新评估预防性给药方案，并鼓励患者在关注疗效指标的同时，也考虑生活品质的改善。同时，基因疗法和非因子疗法的出现，引入了新的临床终点和患者分层标准，这将影响长期的需求模式和治疗流程。

在营运方面，製造商正加大对生物製药产能、製程稳健性和低温运输物流的投资，以满足日益增长的品质和可追溯性要求。支付者和医疗系统要求获得更强有力的真实世界数据和更清晰的价值评估，这促使临床相关人员和行业之间开展更紧密的合作，以产生疗效数据并优化治疗路径。此外，数位健康工具和远端医疗正在改变病患监测和用药支持的方式，有助于更积极主动地管理出血事件，并将治疗融入患者的日常生活。

鑑于这些变化，企业和医疗保健提供者需要平衡短期准入需求与长期创新策略，以确保治疗进步转化为永续的临床和商业性价值。

预测计划于 2025 年进行的关税调整对采购、製造业采购和合约模式的连锁反应，这些反应将影响市场准入和成本动态。

美国计划于2025年实施的政策变化和关税调整，为製造商和医疗保健采购商带来了新的成本动态和采购考量。关税导致的投入成本上升可能会对上游供应链造成压力，尤其是那些依赖跨境采购特殊试剂、一次性技术或辅助包装组件的生产商。为此，製造商正在评估近岸外包、双重采购策略以及合约保护措施，以维持利润弹性和供应连续性。

医疗系统和专科药局正在调整采购流程和库存管理政策，以应对价格波动并保障病患用药。因此，合约模式正朝着与指数挂钩的定价机制和更高的服务水准保障的长期协议方向发展。药物治疗委员会越来越重视医疗保健总成本，以及长效和标准半衰期疗法在给药频率和资源利用方面的可比较性。

此外，关税的影响凸显了监管协调以及与海关和贸易当局积极合作以最大限度减少干扰的重要性。临床团队正日益与供应链领导者合作，以确保治疗药物的供应，同时推进成本控制措施，确保关税调整不会导致患者疗效下降。

对治疗方案、临床工作流程和分销策略的细分影响（按产品类型、适应症、剂型和临床环境划分）

了解这种细分方式的细微差别，有助于阐明不同产品、适应症、剂型、最终用户、通路和给药途径在治疗开发、临床应用和分销重点方面的差异。产品类型之间的差异主要体现在血浆衍生浓缩物和重组产品上，后者可进一步细分为长效和标准半衰期版本。这种结构上的二分法会影响生产复杂性、药物动力学以及在预防保健中的定位。

不同的适应症等级至关重要，血友病A、血友病B和血管性血友病的治疗强度和监测方式各不相同。对于血友病A和B，轻度、中度或重度分类会影响预防性治疗的启动、给药频率和紧急使用。血管性血友病有其自身的临床亚型（I、II和III型），这些亚型会影响治疗策略和凝血因子浓缩剂的选择。製剂形式的选择（液体或冷冻干燥粉）会影响保存期限、低温运输需求和床边配製程序，进而影响医院药局的工作流程和专科治疗中心的管理。

终端使用者趋势集中在医院和专科护理中心，这些机构的输液基础设施、多学科团队和急诊系统能够支援复杂的个案管理。通路包括医院药房、线上药房和零售药房，每个管道的存货周转、报销途径和患者取药方式各不相同。最后，静脉注射仍然是主要的给药途径，这决定了输液训练、血管通路规划和护理工作量。了解这些相互关联的环节有助于制定更个人化的临床通讯协定、更有针对性的商业性策略和更优化的供应链。

区域监管环境、血浆供应韧性和商业模式如何导緻美洲、欧洲、中东和非洲以及亚太地区血浆取得途径的差异

区域趋势将对美洲、欧洲、中东和非洲以及亚太地区的临床实践、监管时间表和供应链设计产生不同的影响。在美洲，高度集中的血友病专科治疗中心和完善的报销机制支持了先进重组疗法的快速应用。然而，该地区也面临支付方准入政策的差异以及生技药品低温运输物流环境的复杂性。

在欧洲、中东和非洲地区，跨司法管辖区的监管协调和集中采购机制既为规模化生产提供了机会，也带来了各国报销制度差异带来的挑战。製造商必须应对不同的竞标流程，并根据不同的卫生技术评估 (HTA) 框架调整证据材料。亚太地区的市场环境复杂多样，有些市场应用迅速，而有些市场的治疗基础设施尚不成熟。製造商通常会采取分阶段的商业化策略，以适应当地不同的生产伙伴关係关係、血浆采集能力和支付方的准备。

无论在哪个地区，血浆供应、当地生产能力和监管沟通策略都将决定市场前置作业时间和商业性准入。因此，相关人员应根据当地实际情况调整分销模式、临床证据产生和相关人员拓展策略，同时保持全球品质标准和可追溯性。

竞争优势源自于製造技术专长、重组创新、策略合作伙伴关係以及决定市场进入和临床应用的真实世界临床结果。

凝血因子浓缩剂市场的竞争动态由现有血浆衍生製剂生产商、重组生物製药以及专注于延长半衰期结构和替代疗法的新兴创新者共同塑造。现有生产商凭藉其在血浆分馏技术、供体网络和大规模生产方面的深厚专业知识，而重组製剂生产商则透过分子工程、延长给药间隔和简化给药方案来提高预防性治疗的依从性。

合作关係和策略联盟持续影响企业的竞争定位，生物製药公司与专科药房和医院网路合作，加速病患用药计画和实证医学证据的累积。同时，新参与企业则着重于针对罕见亚型（例如特定严重程度的患者群体或特定血管性血友病表型）的细分市场定位，以建立临床信誉并获得支付方的支持。生产规模、监管记录以及展现可靠的真实世界疗效的能力，正日益成为医疗系统评估治疗方案时的决定性因素。

因此，商业领袖必须平衡对新型治疗方案的投资与供应链连续性和监管合规性的卓越运营，以保持竞争优势并支持以患者为中心的长期照护模式。

製造商和供应商可采取切实可行的策略步骤，以增强供应韧性、加速重组产品应用，并使临床结果与支付方价值一致。

产业领导者可以透过一系列有针对性且切实可行的措施来增强自身韧性和竞争优势。首先，他们可以实现筹资策略多元化，投资本地製造和委託製造伙伴关係关係，以降低跨境关税波动风险，并缩短关键材料的前置作业时间。同时，他们可以增加对长效重组平台的投资，这些平台能够减少输注频率并提高用药依从性，从而累积卫生经济学证据，凸显其在降低整体医疗成本方面的益处。

同时，我们将与支付方和临床相关人员深入合作，共同设计结果研究和註册登记，以按疾病严重程度分层和血管性血友病亚型评估真实世界的疗效。我们将透过扩大对专科药房和线上药房管道的支持，增强分销灵活性，同时与医院的急性给药通讯协定保持紧密一致。在营运方面，我们将加强低温运输管理、批次追溯和紧急库存通讯协定，以减轻供应中断的影响。

最后，我们优先发展以患者为中心的服务，例如输液教育、依从性技术和居家照护支持，以改善长期疗效并在商业性脱颖而出。这些努力将共同带来临床效益、商业性永续性和组织韧性。

为了确保分析的严谨性，我们采用了稳健的混合调查方法，结合了临床医生访谈、监管证据综合和交叉检验的二手资料。

本分析所依据的研究采用了混合方法，结合了定性访谈、有针对性的二手研究以及监管和临床文献的综合分析，从而构建了该领域的多维度视角。研究人员透过与血液科医生、药房主任、供应链经理和支付方进行结构化访谈，收集了关键见解，以检验临床实践模式、采购趋势和准入限制。这些访谈内容被用来建构情境并评估对关税敏感的供应流。

本研究利用了包括同行评审的临床研究、监管核准和指导文件、产品标籤以及上市公司披露资讯二级资讯来源，对产品特性、安全性概况和给药方案进行三角验证。在分析过程中，我们检验一手和二手资讯来源进行了严格的交叉检验，以确保资讯的一致性并识别出需要进一步调查的差异。必要时，我们会对方法进行调整，以考虑区域监管差异以及综合医院和专科护理中心之间给药模式的差异。

整个过程中都融入了数据品质检查和专家审查环节，以增强结论的可信度，并确保实际建议能够反映临床实际情况和操作限制。

制定全面的策略重点，将创新技术、供应连续性和支付方合作结合，以确保医疗服务的持续可及性和改善患者疗效。

总之，凝血因子浓缩物处于临床需求与技术进步的策略交会点。重组技术、长效製剂和不断发展的护理模式为改善患者预后和减轻输血负担提供了重要机会。然而，血浆供应、生产复杂性和支付方监管等持续存在的挑战限制了近期实施的风险。法规结构和分销基础设施的区域差异进一步增加了商业化策略的复杂性，因此需要采取区域性策略。

为取得成功，相关人员必须将创新研发管线与供应链连续性和实证医学的营运投资结合。透过整合以患者为中心的服务、积极主动地与支付方沟通以及製定稳健的筹资策略，製造商和医疗服务提供者可以在不影响患者可及性的前提下，提供可衡量的临床获益。本执行摘要中的建议为将科学进步转化为永续的临床和商业性成果提供了路线图，从而确保出血性疾病患者能够及时获得有效的蓝图。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大使用长效VIII因子和IX因子产品，以减少给药频率并提高患者依从性
  • 增加A型血友病基因治疗试验的投资，以期提供一次根治性此病的难得机会。
  • 生物相似因子VIII和因子IX浓缩製剂的出现，在定价和市场进入方面对现有品牌产品构成了挑战。
  • 透过整合基于药物动力学的个人化给药平台优化凝血因子浓缩物预防方案
  • 开发皮下注射和非静脉注射凝血因子浓缩剂，以提高患者的便利性和生活品质
  • 扩大血浆采集网路和数位化供应链解决方案，以缓解全球原料短缺问题。
  • 利用真实世界数据和註册数据，证明新型凝血疗法的长期安全性和有效性。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 凝血因子市场（依产品类型划分）

  • 血浆衍生
  • 重组製剂
    • 延长半衰期
    • 标准半衰期

9. 依适应症分類的凝血因子市场

  • A型血友病A
    • 温和的
    • 缓和
    • 严重
  • B型血友病
    • 温和的
    • 缓和
    • 严重
  • 血管性血友病
    • 一型
    • II 型
    • III型

10. 凝血因子製剂市场（依产品分类）

  • 液体
  • 冻干粉

第十一章 依最终使用者分類的凝血因子市场

  • 医院
  • 专业医疗机构

12. 凝血因子市场依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

13. 依给药途径分類的凝血因子市场

  • 静脉注射

14. 各地区凝血因子市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 凝血因子市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国凝血因子市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • CSL Limited
    • Grifols, SA
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Novo Nordisk A/S
    • Sanofi SA
    • Bayer Aktiengesellschaft
    • LFB SA
    • Kedrion SpA
Product Code: MRR-DD0700E81E59

The Coagulation Factor Concentrates Market is projected to grow by USD 17.14 billion at a CAGR of 8.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.84 billion
Estimated Year [2025] USD 9.59 billion
Forecast Year [2032] USD 17.14 billion
CAGR (%) 8.62%

A clear framing of the evolving coagulation factor concentrates landscape linking therapeutic innovation, clinical delivery, regulatory expectations, and supply resilience

The landscape of coagulation factor concentrates stands at the intersection of advanced biologics manufacturing, evolving clinical protocols, and intensified supply chain scrutiny. This introduction frames the therapeutic, operational, and commercial dimensions that shape stakeholder decisions across hospitals, specialty treatment centers, and distribution partners. It highlights the criticality of reliable product availability for patients living with bleeding disorders and positions concentrates as indispensable in both on-demand and prophylactic care pathways.

Transitioning from traditional plasma-derived products toward engineered recombinant options, clinicians and procurement teams now weigh efficacy, safety, dosing frequency, and total cost of care when selecting therapies. Concurrently, regulatory expectations and payer assessments increasingly emphasize real-world outcomes, comparative effectiveness, and pharmacoeconomic evidence. The interplay between innovation in extended half-life biologics and the persistent constraints of plasma supply and manufacturing complexity creates both opportunities and pressures for manufacturers, healthcare providers, and policy stakeholders.

In the sections that follow, this introduction provides a foundation for deep-dive analysis, clarifies the principal therapeutic categories and care settings, and sets the stage for actionable recommendations that align clinical practice with resilient commercial strategies.

How scientific breakthroughs, evolving care paradigms, and supply chain reinforcement are reshaping therapeutic choices and commercial strategies in coagulation concentrates

The coagulation factor concentrates sector is undergoing a set of transformative shifts driven by scientific advances, changing care models, and intensified attention to supply chain integrity. Recombinant engineering and formulation work continue to extend dosing intervals and reduce infusion burdens, prompting clinicians to reassess prophylactic regimens and patients to consider quality-of-life benefits alongside efficacy metrics. At the same time, gene therapies and non-factor modalities introduce new clinical endpoints and patient stratification criteria that will influence long-term demand patterns and treatment algorithms.

On the operational side, manufacturers are investing in biologics capacity, process robustness, and cold-chain logistics to meet heightened quality and traceability expectations. Payers and health systems demand stronger real-world evidence and value articulation, which has prompted closer collaboration between clinical stakeholders and industry to generate outcomes data and optimize care pathways. Additionally, digital health tools and telemedicine are reshaping patient monitoring and adherence support, enabling more proactive management of bleeding episodes and better integration of treatment within patients' daily lives.

Taken together, these shifts require companies and providers to balance near-term access imperatives with longer-term innovation strategies, ensuring that therapeutic advances translate into sustainable clinical and commercial value.

Anticipating the ripple effects of 2025 tariff adjustments across procurement, manufacturing sourcing, and contracting arrangements that influence access and cost dynamics

Policy changes and tariff adjustments in the United States slated for 2025 have introduced new cost dynamics and sourcing considerations for manufacturers and healthcare purchasers. Tariff-driven input cost increases can create pressure points along the upstream supply chain, particularly for producers that depend on cross-border procurement of specialized reagents, single-use technologies, or ancillary packaging components. In response, manufacturers are evaluating nearshoring, dual-sourcing strategies, and contractual protections to preserve margin resilience and continuity of supply.

Health systems and specialty pharmacies are adjusting procurement workflows and inventory policies to manage price volatility and to maintain patient access. As a consequence, contracting models are evolving toward longer-term agreements with indexed pricing mechanisms and enhanced service-level commitments. Pharmacy and therapeutics committees are placing greater emphasis on total cost of care and on the comparability of dosing frequency and resource utilization between extended half-life and standard half-life therapies.

Moreover, tariff implications amplify the importance of regulatory harmonization and of proactive engagement with customs and trade authorities to minimize disruption. Clinical teams are collaborating more closely with supply chain directors to preserve therapeutic availability while navigating cost containment, thereby ensuring that tariff-driven adjustments do not translate into compromised patient outcomes.

Segment-driven implications for therapeutic selection, clinical workflows, and distribution strategies across product types, indications, formulations, and care settings

A nuanced understanding of segmentation clarifies how therapeutic development, clinical adoption, and distribution priorities differ across product, indication, formulation, end user, distribution channel, and administration route. Product-type distinctions center on plasma-derived concentrates and recombinant products, with recombinant offerings further differentiated between extended half-life and standard half-life constructs; this structural dichotomy influences manufacturing complexity, pharmacokinetics, and positioning in prophylactic care.

Indication-level nuances matter because treatment intensity and monitoring differ across Hemophilia A, Hemophilia B, and Von Willebrand Disease. Within Hemophilia A and Hemophilia B, stratification into mild, moderate, and severe categories drives considerations around prophylaxis initiation, dosing frequency, and emergency use. Von Willebrand Disease presents its own clinical subtypes-Type I, Type II, and Type III-that shape therapeutic preferences and factor concentrate selection. Formulation choices, whether liquid presentations or lyophilized powders, affect shelf life, cold-chain requirements, and bedside preparation protocols, which in turn influence hospital pharmacy workflows and specialty center administration.

End-user dynamics are concentrated in hospitals and specialty centers where infusion infrastructure, multidisciplinary teams, and acute care capabilities enable complex case management. Distribution channels vary between hospital pharmacies, online pharmacies, and retail pharmacies; each channel brings different inventory turn rates, reimbursement pathways, and patient access mechanisms. Finally, the predominant route of administration remains intravenous, which dictates infusion training, vascular access planning, and nursing workload. Understanding these intersecting segments enables more tailored clinical protocols, targeted commercial approaches, and optimized supply arrangements.

How regional regulatory landscapes, plasma supply resilience, and commercial models shape access pathways differently across the Americas, EMEA, and Asia-Pacific

Regional dynamics influence clinical practice, regulatory timelines, and supply chain design in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated pockets of specialized hemophilia treatment centers and established reimbursement pathways support rapid adoption of advanced recombinant therapies, while the region also contends with disparities in payer access policies and a complex logistics environment for cold-chain biologics.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and centralized procurement mechanisms can create both opportunities for scale and challenges related to country-level reimbursement heterogeneity. Manufacturers must navigate divergent tender processes and align evidence packages to satisfy multiple HTA frameworks. The Asia-Pacific region presents a heterogenous environment where rapid uptake in some markets coexists with nascent treatment infrastructures in others; manufacturers often pursue phased commercialization strategies that reflect local manufacturing partnerships, plasma collection capacities, and evolving payer readiness.

Across regions, resilience of plasma supply, local manufacturing capabilities, and regulatory engagement strategies will determine lead times and the shape of commercial access. Stakeholders should therefore tailor distribution models, clinical evidence generation, and stakeholder outreach to regional specificities while maintaining global quality and traceability standards.

Competitive positioning driven by manufacturing expertise, recombinant innovation, strategic partnerships, and real-world outcomes that determine access and clinical adoption

Competitive dynamics in the coagulation factor concentrates arena are shaped by incumbent plasma-derived manufacturers, recombinant biologics producers, and emerging innovators focused on extended half-life constructs and alternative modalities. Established producers leverage deep expertise in plasma fractionation, donor networks, and large-scale manufacturing, while recombinant players differentiate through molecular engineering, longer dosing intervals, and simplified administration profiles that support prophylaxis adherence.

Partnerships and strategic alliances continue to define competitive positioning, with collaborations between biopharma firms and specialty pharmacies or hospital networks accelerating patient access programs and evidence generation. At the same time, newcomers emphasize niche positioning-targeting specific severity cohorts or rare subtypes such as particular Von Willebrand disease presentations-to build clinical credibility and payer momentum. Manufacturing scale, regulatory track record, and the ability to demonstrate robust real-world outcomes are increasingly decisive factors when health systems evaluate therapeutic options.

Consequently, commercial leaders must balance investment in novel therapeutic profiles with operational excellence in supply continuity and regulatory compliance to maintain competitive advantage and to support long-term patient-centric care models.

Practical strategic measures for manufacturers and providers to fortify supply resilience, accelerate recombinant adoption, and align clinical outcomes with payer value

Industry leaders can strengthen resilience and competitive positioning through a set of targeted, actionable initiatives. First, diversify sourcing strategies and invest in regional manufacturing or tolling partnerships to reduce exposure to cross-border tariff fluctuations and to shorten lead times for critical inputs. Simultaneously, ramp up investment in extended half-life recombinant platforms that demonstrably reduce infusion frequency and improve adherence, while also building the health economic case that highlights total cost of care improvements.

In parallel, deepen engagement with payers and clinical stakeholders by co-designing outcomes studies and registries that capture real-world effectiveness across severity strata and Von Willebrand disease subtypes. Strengthen distribution flexibility by expanding support for specialty and online pharmacy channels while preserving tight integration with hospital pharmacy protocols for acute administration. Operationally, enhance cold-chain oversight, batch traceability, and emergency stock protocols to mitigate the impact of supply disruptions.

Finally, prioritize patient-centric services-such as infusion education, adherence technologies, and homecare enablement-to improve long-term outcomes and to differentiate commercially. Taken together, these measures align clinical benefits with commercial sustainability and organizational resilience.

A robust mixed-method research approach integrating clinician interviews, regulatory evidence synthesis, and cross-validated secondary sources to ensure analytical rigor

The research underpinning this analysis deployed a mixed-method methodology that combined qualitative interviews, targeted secondary research, and synthesis of regulatory and clinical literature to create a multi-dimensional view of the sector. Primary insights were gathered through structured interviews with hematologists, pharmacy directors, supply chain leaders, and payers to validate clinical practice patterns, procurement dynamics, and access constraints. These conversations informed scenario development and the assessment of tariff-sensitive supply flows.

Secondary sources included peer-reviewed clinical studies, regulatory approvals and guidance documents, product labels, and publicly available company disclosures to triangulate product capabilities, safety profiles, and dosing paradigms. The analysis applied rigorous cross-validation between primary and secondary inputs to ensure consistency and to surface divergences that warranted further investigation. Where appropriate, methodological adjustments accounted for regional regulatory differences and for variations in hospital versus specialty center delivery models.

Data quality checks and expert review cycles were integrated throughout the process to strengthen the robustness of conclusions and to ensure that practical recommendations reflect both clinical realities and operational constraints.

Summative strategic priorities that reconcile innovation, supply continuity, and payer engagement to secure durable access and improved patient outcomes

In conclusion, coagulation factor concentrates occupy a strategic nexus of clinical necessity and technological progress. Recombinant science, extended half-life formulations, and evolving care models present meaningful opportunities to improve patient outcomes and to reduce the burden of infusions, while persistent challenges around plasma supply, manufacturing complexity, and payer scrutiny temper near-term execution risks. Geographic differences in regulatory frameworks and distribution infrastructures further complicate commercialization strategies, requiring regionally tailored approaches.

To succeed, stakeholders must align innovation pipelines with operational investments in supply continuity and evidence generation. By integrating patient-centric services, proactive payer engagement, and resilient procurement strategies, manufacturers and providers can deliver measurable clinical benefits without compromising access. The recommendations in this executive summary provide a roadmap for translating scientific advances into durable clinical and commercial outcomes, preserving the central objective of ensuring timely and effective therapy for patients living with bleeding disorders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of extended half-life factor VIII and IX products to reduce infusion frequency and improve patient adherence
  • 5.2. Increased investment in gene therapy trials targeting hemophilia A and B to offer one-time curative treatment opportunities
  • 5.3. Emergence of biosimilar factor VIII and IX concentrates challenging established branded products on pricing and market access
  • 5.4. Integration of pharmacokinetic-guided personalized dosing platforms to optimize coagulation factor concentrate prophylaxis regimens
  • 5.5. Development of subcutaneous and nonintravenous factor concentrate formulations aimed at improving patient convenience and quality of life
  • 5.6. Expansion of plasma collection networks and digital supply chain solutions to mitigate global shortages of source material
  • 5.7. Application of real-world evidence and registry data to demonstrate long-term safety and efficacy of novel coagulation therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coagulation Factor Concentrates Market, by Product Type

  • 8.1. Plasma Derived
  • 8.2. Recombinant
    • 8.2.1. Extended Half Life
    • 8.2.2. Standard Half Life

9. Coagulation Factor Concentrates Market, by Indication

  • 9.1. Hemophilia A
    • 9.1.1. Mild
    • 9.1.2. Moderate
    • 9.1.3. Severe
  • 9.2. Hemophilia B
    • 9.2.1. Mild
    • 9.2.2. Moderate
    • 9.2.3. Severe
  • 9.3. Von Willebrand Disease
    • 9.3.1. Type I
    • 9.3.2. Type II
    • 9.3.3. Type III

10. Coagulation Factor Concentrates Market, by Formulation

  • 10.1. Liquid
  • 10.2. Lyophilized Powder

11. Coagulation Factor Concentrates Market, by End User

  • 11.1. Hospitals
  • 11.2. Specialty Centers

12. Coagulation Factor Concentrates Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Coagulation Factor Concentrates Market, by Route Of Administration

  • 13.1. Intravenous

14. Coagulation Factor Concentrates Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Coagulation Factor Concentrates Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Coagulation Factor Concentrates Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. CSL Limited
    • 17.3.2. Grifols, S.A.
    • 17.3.3. Octapharma AG
    • 17.3.4. Takeda Pharmaceutical Company Limited
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Novo Nordisk A/S
    • 17.3.7. Sanofi S.A.
    • 17.3.8. Bayer Aktiengesellschaft
    • 17.3.9. LFB S.A.
    • 17.3.10. Kedrion S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COAGULATION FACTOR CONCENTRATES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 293. MID